Advancements in Non-Small Cell Lung Cancer Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

• Tipo: Artigo em Revista Científica Internacional
• Data: 2024

Autores

Jager, VDD (Autor) Outra; Timens, W (Autor) Outra; Bayle, A (Autor) Outra; Botling, J (Autor) Outra; Brcic, L (Autor) Outra; Büttner, R (Autor) Outra; Fernandes, MGO (Autor) Outra; Havel, L (Autor) Outra; Hochmair, MJ (Autor) Outra; Hofman, P (Autor) Outra; Janssens, A (Autor) Outra; Johansson, M (Autor) Outra; van Kempen, L (Autor) Outra; Kern, I (Autor) Outra; Lopez-Rios, F (Autor) Outra; Lüchtenborg, M (Autor) Outra; Machado JC (Autor) FMUP; Mohorcic, K (Autor) Outra; Paz-Ares, L (Autor) Outra; Popat, S (Autor) Outra; Ryska, A (Autor) Outra; Taniere, P (Autor) Outra; Wolf, J (Autor) Outra; Schuuring, E (Autor) Outra; van der Wekkenz, AJ (Autor) Outra

Revista

A Revista está pendente de validação pelos Serviços Administrativos.

Título: LANCET REGIONAL HEALTH-EUROPE

Vol. 38

ISSN: 2666-7762

Indexação

ISI Web of Knowledge - 0 Citações

Scopus - 1 Citação

Outras Informações

ID Authenticus: P-010-253

DOI: 10.1016/j.lanepe.2024.100838

Abstract (EN): In the past two decades, the treatment of metastatic non -small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision -making, and ensuring quality control. Copyright (c) 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 16